March 2011
Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p34
The article lists several factors which contribute to the pharmaceutical industry in the U.S. including the repeal of the health care reform law, the prevalence of Orphan diseases, and the withdrawal of the drug Avastin.


Related Articles

  • Industry says 'no' to sunshine regs change. M. I. // Medical Marketing & Media;May2011, Vol. 46 Issue 5, p11 

    The article reports on the opposition of pharmaceutical companies to the draft changes in the healthcare reform in the U.S.

  • Three Things.  // Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p9 

    The article offers news briefs related to the pharmaceutical industry in the U.S. including the overtime lawsuit involving the GlaxoSmithKline (GSK) representatives, the falling salaries of female healthcare providers, and the move of Abbott Laboratories Inc. to blame healthcare reform for...

  • INDUSTRY INSIGHTS.  // Pharmaceutical Executive;Jul2010, Vol. 30 Issue 7, p13 

    The article offers updates related to the pharmaceutical industry in the U.S. including a study that looks at which pharmaceutical companies are on top when it comes to offering medicines in emerging markets, a meeting of the Drug Information Association that discusses the changes in the...

  • Three Things.  // Pharmaceutical Representative;Dec2010, Vol. 40 Issue 12, p9 

    The article offers news briefs on pharmaceutical industry in the U.S. such as whether the industry will be considered a bipartisan sport, the industry's struggles with social media, and the due of Healthcare Reform Bill.

  • Budget Battles Put Pharma's $80B Back in Play.  // Pharmaceutical Representative;May2011, Vol. 41 Issue 5, p9 

    The article reports on the 80 billion-dollar offered by the pharmaceutical industry in savings on drug spending and support of healthcare reform in the U.S., which has been questioned in light of new efforts to cut government spending and its impact on the industry.

  • In the Pipeline - Health Care Reform and the Drug Industry: How Goes It?  // Contract Pharma;Mar2013, Vol. 15 Issue 2, p33 

    The article presents the author's perspective on the ideological context of health care reform and the drug industry in the U.S.

  • Sponsors Cope with New Sunshine Act Rules.  // Applied Clinical Trials;Oct2010, Vol. 19 Issue 10, p19 

    In this article, the author discusses aspects of the health reform legislation that requires pharmaceutical companies to report to the federal government fees paid to physicians for conducting clinical trials. She stresses that the Physician Payments Sunshine Act establishes a process for...

  • Drug Prices Going Up? Wechsler, Jill // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p14 

    The article reports on the increase in high prescription drug prices by the Government Accountability Office (GAO) in the U.S. It states the price increase of more than 300 drugs from 2000 to 2008 in which policymakers pointed that pharmaceutical companies lock in higher prices in expectations...

  • When the Payer is the Player.  // Pharmaceutical Executive;Oct2010, Vol. 30 Issue 10, p32 

    An interview with the Arcas Group president Jan Heybroek and PriceSpective partner Ted Sweeny concerning the U.S. healthcare system is presented. Heybroek and Sweeney reveal the hopes and fears of pharmaceutical companies regarding the expanding power of private payers such as insurance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics